SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending due to increased interest in quantum computing stocks, spurred by news of a substantial investment in quantum technologies. The community is actively discussing the potential for a short squeeze and comparing RGTI to other quantum and AI-related stocks. High trading volume and positive market sentiment are contributing to the stock's upward momentum.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid discussions of its strategic shift towards quantum computing for cryptocurrency applications, particularly its partnership with LightSolver and potential for energy-efficient blockchain solutions. The community is comparing QCLS to other quantum and crypto stocks, with traders closely monitoring its low float and threshold list status. Speculation around news and potential contracts is also fueling interest.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending due to a recent surge, with the community discussing its strong balance sheet, real-world applications, and potential for further gains. Bullish sentiment is fueled by news of institutional interest and successful deployments of their quantum solvers. Some are drawing comparisons to the dot-com bubble, while others see $QBTS as a long-term play in the burgeoning quantum computing sector.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending due to a mixed analyst outlook, highlighted by Jefferies downgrading the stock to Underperform while Morgan Stanley raised its price target significantly, sparking debate among investors about the company's valuation and future performance. The community is actively discussing the credibility of these differing analyses and their potential impact on Apple's stock price, while also eyeing potential upside catalysts such as strong iPhone 17 sales and long-term bullish positioning by institutions.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending following the announcement of a partnership with AI search engine Perplexity, aimed at enhancing video discovery on the platform. The community is buzzing about the potential impact of this collaboration, especially regarding AI-driven content recommendations and a new subscription bundle. Some traders speculate about a possible short squeeze, referencing the high short interest and significant call option activity.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending due to a planned $500 million private placement, sparking discussions about dilution and the company's growth prospects. Community members are debating the stock's valuation relative to its revenue and comparing it to other quantum computing stocks like IONQ and RGTI. Some traders are optimistic about the future of quantum computing and government support, while others express skepticism and highlight potential risks.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss positive momentum and a potential short squeeze, with community members pointing to the stock being undervalued. Renewed optimism surrounds upcoming data releases, revenue potential and speculation around a buyout, while some traders monitor options activity for bullish signals. Community members are actively discussing resistance levels and expressing optimism about the stock's long-term potential amid volatility.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to its position in the quantum computing sector, with community members actively discussing its high valuation and potential for future growth. News surrounding government funding and partnerships, including potential collaborations with NVIDIA, are also driving interest.  Additionally, some investors are closely watching for potential short squeezes and dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors discuss the implications of an upcoming warrant distribution and a mixed securities shelf offering. The community is split, with some viewing the warrant as a positive catalyst for a potential squeeze, while others express concern about possible dilution and the actions of company leadership. The stock's volatile price action and potential for manipulation are also key discussion points.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to its upcoming merger with Terra Innovatum, a nuclear energy company, generating community discussion about the potential of the micro-modular reactor technology and comparison to sector peers. Community members are weighing the risks and potential rewards associated with holding through the merger and ticker change, while also considering the broader context of renewed interest in nuclear energy. Some traders point to unusual options activity and analyst coverage as potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks

The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's  What You Should Know

Shares of Sagimet Biosciences soared nearly 40% on Monday, reaching levels not seen since March 2024, as retail sentiment surged following news of an upcoming presentation linked to its lead drug candidate.&nbsp;The clinical-stage biopharma company, which is developing novel therapeutics targeting metabolic and fibrotic diseases, announced that it will present at the 9th Annual MASH-TAG Conference in Park City, Utah, from Jan. 9&nbsp;to 11.The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b FASCINATE-2 study for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMT_sentiment_and_message_volume_Jan_6_fc5e3fb3e0.png" alt="SGMT sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>SGMT sentiment and message volume Jan 6 as of 11:35 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish,’ with Sagimet’s stock trending among the top 20 tickers as of mid-morning.&nbsp;Many investors&nbsp;eagerly await further announcements at the conference, with some buying based on rumors of a significant update.<stembedurl>https://stocktwits.com/GXD_Texas/message/598950606</stembedurl><stembedurl>https://stocktwits.com/valueforme/message/598944787</stembedurl>The study demonstrated a positive anti-fibrotic effect, providing strong support for the drug’s potential in treating liver diseases caused by excessive fat buildup and inflammation.Sagimet’s FASN inhibitors aim to address the dysfunctional metabolic pathways responsible for the overproduction of palmitate, a fatty acid linked to diseases like MASH.&nbsp;Denifanstat’s progress has been noteworthy, with Breakthrough Therapy designation granted by the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3).Oppenheimer’s recent coverage of Sagimet with an ‘outperform’ rating and a $30 price target, which implies more than a 340% upside from current levels, has also contributed to the stock’s upward movement.&nbsp;The brokerage firm highlighted denifanstat’s potential in the MASH market, which is currently dominated by Madrigal Pharmaceuticals’ Resmetirom.&nbsp;Oppenheimer estimates denifanstat could achieve peak revenues of around $1.9 billion by 2040, solidifying its long-term growth prospects.<a href="https://stocktwits.com/symbol/SGMT">Sagimet stock</a> has gained nearly 50% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate

Many investors eagerly await further announcements at the conference, with some buying based on rumors of a significant update.

Equity

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily...

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA Research Report) and Sagimet Biosciences, Inc. Class A...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $41.50 Average PT from Analysts

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has received an average rating of "Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six...

Sagimet Biosciences CEO, President & Director Acquires 553% More Stock

Even if it's not a huge purchase, we think it was good to see that David Happel, the CEO, President & Director of...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$7.16
Prev Close	$6.98
Open	$6.99
Dividend Yield	0.00%
50-Day Moving Average	$7.73
Beta	0.00
Avg. Volume	486,733.95
PE Ratio	-3.88

52-Week High	$11.41
52-Week Low	$1.73
Market Capitalization	$232.85M
EPS (Annual)	-$1.45
Price to Book	1.77
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMT Sagimet Biosciences Inc